Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene

Inclusion Criteria: * Written informed consent to participate in the study. * Men or women aged 18 years or older * Diagnosed with Fundus albipunctatus 1. Isolated rod response markedly reduced (less than 20% of normal)after 20 minutes dark adaptation and improved by 50% after 2 hours 2. Negative maximal response (a wave to b wave ratio less than 2) 3. Retinal midperipheral white dots (More than 3000 dots) Exclusion Criteria: * Current smokers. * Current use of Vitamin A/ beta carotene supplements. * Active arterial disease within 3 months of study entry such as unstable angina, myocardial infarction, transient ischemic attack (TIA), stroke, and coronary artery bypass graft (CABG) surgery. * History of malignancy, except basal or squamous cell skin carcinoma. * Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception. * Uncontrolled hypertension defined as either resting diastolic blood pressure of \>95mmHg (taken from the mean of 3 readings) or resting systolic blood Pressure of \> 180 mmHg. * History of alcohol abuse or drug abuse, or both. * Active liver disease or hepatic dysfunction as defined by elevations of 2.0 times the ULN in any of the following liver function tests: ALT, AST or bilirubin. * Serum CPK \> 2.0 times ULN in visit 0 * TSH above the normal range. * Newly diagnosed diabetes within 3 months. * Patient plans to engage in vigorous exercise or an aggressive diet regimen. * Uncontrolled endocrine or metabolic disease. * Participation in another investigational drug study within 4 weeks of entry into this study. * Serious or unstable medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. * Serum creatinine \> 2.0 mg/dl before the treatment phase, +3 proteinuria in urine dipstick, or a history of renal transplantation before the treatment period. * Subject whose hormone replacement therapy (HRT) or oral contraceptive therapy (OCT) was initiated within the 3 month prior to enrollment. * Forbidden medications: the combination of PPAR alpha agonists-fibric acid derivatives, PPAR gamma agonists.